eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients1
  • Active clinically significant bleeding1
  • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk1
  • Lesion or condition if considered a significant risk factor for major bleeding; this may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities1
  • Concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.), except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter1
Diagnosemethoden

ELIQUIS is approved for a broad range of indications1

Download guides designed for your patients

Access further resources, including treatment guidelines, patient materials and downloadable supporting materials


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

UFH = Unfractionated Heparin

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.